Tin tức & Cập nhật
Xem bài viết Nhi khoa
Xem
Chỉ hiển thị Multimedia

Dupilumab trumps MTX, cyclosporine in paediatric AD
03 Feb 2025
bởiStephen Padilla
The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.
Dupilumab trumps MTX, cyclosporine in paediatric AD
03 Feb 2025
COVID-linked MIS-C outcomes reassuring at 6 months
31 Jan 2025
bởiElvira Manzano
Children and young adults with multisystem inflammatory syndrome in children (MIS-C) related to COVID-19 infection show good cardiovascular and noncardiovascular outcomes at 6 months, according to data from the long-term MUSIC study.







